Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03867682
Other study ID # LIN-AC225-AML02
Secondary ID
Status Recruiting
Phase Phase 1/Phase 2
First received
Last updated
Start date January 15, 2020
Est. completion date June 2024

Study information

Verified date August 2023
Source Actinium Pharmaceuticals
Contact Actinium Pharmaceuticals, Inc.
Phone +1-646-677-3878
Email actimab@actiniumpharma.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The study is a multicenter, open label Phase I/II trial. 1. To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapsed/refractory AML. (Phase 1 portion) 2. To assess the percentage of patients with CR, CRh, or Overall Response (CR + CRh), up to 6 months after the start of treatment without receiving other AML therapies. (Phase 2 portion)


Description:

The study is a multicenter, open label Phase I and Phase II trial combining lintuzumab-Ac225 with venetoclax in patients who have relapsed or refractory AML. The Phase I portion is a dose-finding study which will enroll at least three patients at each dose level. Patients in a dose level will be observed for a minimum of 4 weeks before dose escalation occurs. There is no dose escalation for any individual patient. The Phase II portion of the study will enroll patients at the MTD dose level of lintuzumab-Ac225 as determined in the Phase I portion of the study. The goal of the Phase II portion will be to further characterize the safety and efficacy of the MTD dose of lintuzumab-Ac225.


Recruitment information / eligibility

Status Recruiting
Enrollment 38
Est. completion date June 2024
Est. primary completion date November 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Refractory or relapsed AML which will include: 1. Refractory disease will be defined as at least 1 prior treatment with no remission. 2. Relapsed disease will be defined as 5% or more blasts in bone marrow seen after remission. 3. Patients with AML arising from myelodysplastic syndromes (including CMML) or myeloproliferative neoplasms (secondary AML, ts-AML) are also eligible. 2. Circulating blast count = 200/µL within 10 days prior to first cycle of treatment. Hydroxyurea should be used to keep the peripheral blast count = 200/µL until the first day of protocol treatment, to the extent that this is possible 3. ECOG = 2 4. Estimated creatinine clearance = 50 mL/min 5. AST and ALT = 3.0 x ULN 6. Bilirubin = 3.0 x ULN Exclusion Criteria: 1. Active CNS Leukemia. 2. Known HIV infection or known hepatitis B or hepatitis C infection (with a detectable viral load). 3. Participant has received strong and/or moderate CYP3A inducers within 7 days prior to the initiation of study treatment. 4. Secondary refractory AML (e.g., treated for current relapse without achieving remission); a. With the exception that single agent FLT3 inhibitors, IDH1/IDH2 inhibitors are allowed for current relapse without achieving remission. 5. Have received prior radiation to maximally tolerated levels to any critical normal organ. 6. Clinically significant cardiac disease. 7. Active, uncontrolled serious infection. 8. Have other non-myeloid malignancy within 2 years of entry (with exceptions). 9. Psychiatric disorder that would preclude study participation 10. Previous solid organ transplant (prior treatment with SCT is allowed but not if patient has GVHD or is still receiving immunosuppression/GVHD therapy).

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Lintuzumab-Ac225
In the Phase I, patients will be enrolled into the following dose escalation cohorts: 0.50 µCi/kg, 1.0 µCi/kg, and 1.5 µCi/kg. If the 0.50 µCi/kg dose is determined to exceed the MTD, a 0.25 µCi/kg dose will be explored.
Drug:
Venetoclax
400 mg daily will be taken orally on Days 1-21 of a 28-day cycle. There will be a ramp up of venetoclax dosing in the first cycle, with 100 mg administered on Day 1, 200 mg on Day 2, and 400 mg on Day 3 and Day 4 and later. Patients on antifungal azoles should receive one-half these doses, up to a maximum of 200 mg of venetoclax.
Spironolactone
25 mg by mouth daily, administered on Cycle 1 Day 15 and continued for 12 months after the subject's last treatment with lintuzumab-Ac225.

Locations

Country Name City State
United States University of California Los Angeles California
United States University of Louisville Louisville Kentucky
United States Ochsner Clinic Foundation New Orleans Louisiana
United States Weill Cornell Medicine New York New York
United States Fred Hutchinson Cancer Research Center Seattle Washington

Sponsors (1)

Lead Sponsor Collaborator
Actinium Pharmaceuticals

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Phase I: Maximum Tolerated Dose (MTD) of Lintuzumab-Ac225 To determine the maximum tolerated dose (MTD) of lintuzumab-Ac225 added to venetoclax for patients with CD33 positive relapse/refractory AML. Cycle 1, up to 48 days
Primary Phase II: Overall Response (CR + CRh + CRi) To assess the percentage of patients with CR, CRh, CRi or Overall Response (CR + CRh + CRi), up to 6 months after the start of treatment without receiving other AML therapies. Up to 6 months
Secondary Phase I: Overall Response Number of patients who's overall response is CR, CRh, or CRi Up to 6 months
Secondary Phase I and II: OS Number of patients who died End of 6 months, 12 months, 2 years
Secondary Phase I and II: DFS Disease-free survival End of 6 months, 12 months, 2 years
Secondary Phase I and II: Evaluate incidence of AEs and SAEs Rate of AEs and SAEs, including infusion-related reactions Through study completion, up to 2 years
Secondary Phase I and II: Evaluate BH3 priming assay results Summary of assay results Completion of Cycle 1, estimated 1 month
Secondary Phase I and II: MRD status Number of patients who are MRD negative From date of first dose until the date of first documented response, first assessment at 6 months
Secondary Phase I and II: Lab abnormalities (other than hematologic indices) Summary of rate of Grade 3/4 lab abnormalities Through study completion, up to 2 years
See also
  Status Clinical Trial Phase
Recruiting NCT05400122 - Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer Phase 1
Recruiting NCT04460235 - Immunogenicity of an Anti-pneumococcal Combined Vaccination in Acute Leukemia or Lymphoma Phase 4
Completed NCT03678493 - A Study of FMT in Patients With AML Allo HSCT in Recipients Phase 2
Completed NCT04022785 - PLX51107 and Azacitidine in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Phase 1
Recruiting NCT05424562 - A Study to Assess Change in Disease State in Adult Participants With Acute Myeloid Leukemia (AML) Ineligible for Intensive Chemotherapy Receiving Oral Venetoclax Tablets in Canada
Terminated NCT03224819 - Study of Emerfetamab (AMG 673) in Adults With Relapsed/Refractory Acute Myeloid Leukemia (AML) Early Phase 1
Completed NCT03197714 - Clinical Trial of OPB-111077 in Patients With Relapsed or Refractory Acute Myeloid Leukaemia Phase 1
Active, not recruiting NCT03844048 - An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial Phase 3
Active, not recruiting NCT04070768 - Study of the Safety and Efficacy of Gemtuzumab Ozogamicin (GO) and Venetoclax in Patients With Relapsed or Refractory CD33+ Acute Myeloid Leukemia:Big Ten Cancer Research Consortium BTCRC-AML17-113 Phase 1
Active, not recruiting NCT04107727 - Trial to Compare Efficacy and Safety of Chemotherapy/Quizartinib vs Chemotherapy/Placebo in Adults FMS-like Tyrosine Kinase 3 (FLT3) Wild-type Acute Myeloid Leukemia (AML) Phase 2
Recruiting NCT04920500 - Bioequivalence of Daunorubicin Cytarabine Liposomes in Naive AML Patients N/A
Recruiting NCT04385290 - Combination of Midostaurin and Gemtuzumab Ozogamicin in First-line Standard Therapy for Acute Myeloid Leukemia (MOSAIC) Phase 1/Phase 2
Recruiting NCT03897127 - Study of Standard Intensive Chemotherapy Versus Intensive Chemotherapy With CPX-351 in Adult Patients With Newly Diagnosed AML and Intermediate- or Adverse Genetics Phase 3
Active, not recruiting NCT04021368 - RVU120 in Patients With Acute Myeloid Leukemia or High-risk Myelodysplastic Syndrome Phase 1
Recruiting NCT03665480 - The Effect of G-CSF on MRD After Induction Therapy in Newly Diagnosed AML Phase 2/Phase 3
Completed NCT02485535 - Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant Phase 1
Enrolling by invitation NCT04093570 - A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose), With a Food Effect Substudy at Select Study Centers Phase 2
Recruiting NCT04069208 - IA14 Induction in Young Acute Myeloid Leukemia Phase 2
Recruiting NCT05744739 - Tomivosertib in Relapsed or Refractory Acute Myeloid Leukemia (AML) Phase 1
Recruiting NCT04969601 - Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings Phase 1/Phase 2